PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells

Anti-Cancer Drugs

Volumn 25, Issue 7, 2014, Pages 751-766

  Du, Jiang Bo ^a   Song, Yan Feng ^a   Ye, Wei Liang ^a   Cheng, Ying ^a   Cui, Han ^a   Liu, Dao Zhou ^a   Liu, Miao ^a   Zhang, Bang Le ^a   Zhou, Si Yuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

doxorubicin; folic acid; lipid polymer hybrid nanoparticles; multidrug resistance

Indexed keywords

2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; AMPHOPHILE; ANTINEOPLASTIC AGENT; DOXORUBICIN; FOLIC ACID; LIPID POLYMER HYBRID NANOPARTICLE; MACROGOL; NANOPARTICLE; PHOSPHOETHANOLAMINE; POLYGLACTIN; UNCLASSIFIED DRUG; DRUG CARRIER; FOLIC ACID-POLY(ETHYLENEGLYCOL)-2-DISTEAROYLGLYCERO-3-PHOSPHOETHANOLAMINE; LACTIC ACID; MACROGOL DERIVATIVE; PHOSPHATIDYLCHOLINE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ACIDITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL KILLING; CELL NUCLEUS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSIFICATION SOLVENT EVAPORATION METHOD; EMULSION; EVAPORATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; PARTICLE SIZE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FOLIC ACID; HUMANS; LACTIC ACID; NANOPARTICLES; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84903816931     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000092     Document Type: Article

References (67)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2:751-760. (Pubitemid 350223348)
2. Hadinoto K,Sundaresan A,Cheow WS, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, Eur J Pharm Biopharm, 2013,85, 427-443.
3. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83:273-286. (Pubitemid 35282471)
4. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm 2007; 66:34-41. (Pubitemid 46412968)
5. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood prope rties. J Control Release 2002; 79:123-135. (Pubitemid 34164166)
6. Budhian A, Siegel SJ,Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul 2005; 22:773-785. (Pubitemid 43158197)
7. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Co ntrol Release 2001; 77:27-38. (Pubitemid 33022613)
8. Sheng Y, Yuan Y, Liu C, Tao X, Shan X, Xu F. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood sub stitutes: effect of PEG content. J Mater Sci Mater Med 2009; 20:1881-1891.
9. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, et al. Biodistribution of phosphodiester and pho sphorothioate siRNA. Bioorg Med Chem Lett 2004; 14:1139-1143. (Pubitemid 38229843)
10. Van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34:1393-1397. (Pubitemid 44079881)
11. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307:93-102. (Pubitemid 41773257)
12. Mori A, Klibanov AL, Torchilin VP, Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 1991; 284:263-266.
13. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1992; 1105:193-200.
14. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm 2005; 298:233-241. (Pubitemid 40828344)
15. Suh J, Choy KL, Lai SK, Suk JS, Tang BC, Prabhu S, et al. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine 2007; 2:735-741.
16. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homobifunctional spacer for active targeting in cancer therapy. Nanote chnology 2011; 22:035101.
17. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 2013; 334:157-175.
18. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003; 55:403-419. (Pubitemid 36293792)
19. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X, et al. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and watersoluble chitosan. Biomaterials 2009; 30:2340-2348.
20. Roser M, Fischer D, Kissel T. Surface -modified biodegradable albumin nano-and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998; 46:255-263. (Pubitemid 29057671)
21. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006; 27: 4356-4373. (Pubitemid 43674179)
22. Sengupta S, Eavarone D, Capila I, Zhao G, Watso n N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436:568-572. (Pubitemid 41112931)
23. Parr MJ,Masin D,Cullis PR,Bally MB, A ccumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol, J Pharmacol Exp Ther, 1997, 280, 1319-1327. (Pubitemid 27166729)
24. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999; 5:3645-3652.
25. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene gl ycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 2005; 312:1020-1026. (Pubitemid 40293760)
26. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007; 122:349-355. (Pubitemid 47407760)
27. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006; 13:328-337. (Pubitemid 43056898)
28. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release 2009; 137:234-240.
29. Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lip oplexes. J Control Release 2010; 142:160-166.
30. Huang L, Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011; 13:507-530.
31. Mandel R, Ryser HJ, Niaki B, Ghani F, ShenWC. Isolation of variants of Chinese hamster ovary cells with abnormally low levels of GSH: decreased ability to cleave endocytosed disulfide bonds. J Cell Physiol 1991; 149:60-65. (Pubitemid 21910166)
32. Short S, Merkel BJ, Caffrey R, McCoy KL. Defective antigen processing correlates with a low level of intracellular glutathione. Eur J Immunol 1996; 26:3015-3020. (Pubitemid 26411507)
33. Guo X, Szoka FC Jr. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem 2001; 12:291-300. (Pubitemid 32235482)
34. Walker GF, Fella C, Pelisek J, Fahrmeir J, Boeckle S, Ogris M, et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther 2005; 11:418-42 5. (Pubitemid 40277318)
35. Zhang JX, Zalipsky S, Mullah N, Pechar M, Allen TM. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharm acol Res 2004; 49:185-198. (Pubitemid 37485715)
36. Zalipsky S, Qazen M,Walker JA 2nd, Mullah N, Quinn YP, Huang SK. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 1999; 10:703-707. (Pubitemid 29456355)
37. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, et al. Development of a novel syste mic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007; 14:68-77. (Pubitemid 44942867)
38. Li H, Sun X, Zhao D, Zhang Z. A cell-specific poly(ethylene glycol) derivative with a wheat-like structure for efficient gene delivery. Mol Pharm 2012; 9:2974-2985.
39. Scomparin A, Salmaso S, Bersani S, Satchi-Fainaro R, Caliceti P. Novel folated and non-folated pullul an bioconjugates for anticancer drug delivery. Eur J Pharm Sci 2011; 42:547-558.
40. Hwa Kim S, Hoon Jeong J, Joe CO, Gwan Park T. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate. J Control Release 2005; 103:625-634. (Pubitemid 40471020)
41. Mieszawska AJ, Gianella A, Cormode DP, Zhao Y, Meij erink A, Langer R, et al. Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb) 2012; 48:5835-5837.
42. Z hang Z, Huey Lee S, Feng SS. Folate-decorated poly(lactide-co- glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 2007; 28:1889-1899. (Pubitemid 46137995)
43. Misra R, Sahoo SK. Intra cellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010; 39:152-163.
44. Alexis F,Pridgen E,Molnar LK,Farokhzad OC, Factors affecting the clearance and biodistribution of polymeric nanoparticles,Mol Pharm,2008,5,505-515.
45. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009; 61:428-437.
46. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev 2008; 60: 1226-1240.
47. Hobbs SK, Monsky WL , Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95:4607-4612. (Pubitemid 28207960)
48. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010; 31:3657-3666.
49. A ttia AB, Yang C, Tan JP, Gao S, Williams DF, Hedrick JL, et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. Biomaterials 2013; 34:3132-3140.
50. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996; 271:1079-1080. (Pubitemid 26075221)
51. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D , Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-1461.
52. Park EK, Lee SB, Lee YM. Prep aration and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005; 26:1053-1061. (Pubitemid 39208991)
53. Saxena V, Naguib Y, Hussain MD. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloids Surf B Biointerfaces 2012; 94:274-28 0.
54. Tao W, Zeng X, Liu T, Wang Z, Xiong Q, Ouyang C, et al. Docetaxelloaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy. Acta Biomate r 2013; 9: 8910-8920.
55. Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to ce rvical cancer. Biomaterials 2013; 34: 6058-6067.
56. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorub icin. Nanomedicine 2009; 5:410-418.
57. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000; 41:147-162. (Pubitemid 30122955)
58. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010; 53:6811-6824.
59. Ulbrich K, Michaelis M, Rothweiler F, Knobloch T, Sithisarn P, Cinatl J, et al. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm 2011; 406:128-134.
60. Yang SJ, Lin FH, Tsai HM, Lin CF, Chin HC, Wong JM, et al. Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials 2011; 32:2174-2182.
61. Martínez A, Olmo R, Iglesias I, Teijön JM , Blanco MD. Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: synthesis and in vitro characterization. Pharm Res 2014; 31:182-193.
62. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117:78-88.
63. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release 2006; 112:208-213.
64. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, et al. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture b y macrophages. Pharm Res 1999; 16:1710-1716. (Pubitemid 29530403)
65. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) fo r enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006; 116:275-284. (Pubitemid 44827405)
66. Wang S,Konorev EA,Kotamraju S,Joseph J,Kalivendi S,Kalyanaraman B, Doxorubicin indu ces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)-and p53-dependent pathways,J Biol Chem,2004,279, 25535-25543. (Pubitemid 38756813)
67. Mizutani H, Tada-Oikawa S, Hira ku Y, Kojima M, Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005; 76:1439 -1453. (Pubitemid 40164773)